Working with SEPs: How do we expand Hepatitis Services ? Narelle Ellendon, RN HCV Director Harm Reduction Coalition, NYC

Slides:



Advertisements
Similar presentations
Sharon Stancliff, MD Caroline Rath, PA-C Harm Reduction Coalition New York, NY USA.
Advertisements

Meeting need and improving coverage workshop. Meeting need: calculating and improving coverage.
Needle and syringe programmes Implementing NICE guidance 2009 NICE public health guidance 18.
HIV in Europe Stockholm, 3.November 2009 Communication on combating HIV/AIDS in the EU and the neighbourhood - strategy and second action plan ( )
Workshop IV: Provision of Health Care The Impact of International Standards and Guidelines on prisoner health in Eastern and Central Europe Antalya, Turkey.
No one left behind: Increased coverage, better programmes and maximum impact for key populations WHO Consolidated Guidelines on HIV Prevention, Diagnosis,
Robin Pollard Operations Coordinator Youth RISE.
Robin Pollard Operations Coordinator Youth RISE.
Overview of Outreach competencies Stephen J. Gumbley, MA, ACDP II Director, New England ATTC.
Out of Sight, Out of Time: Injection Drug Users, Hepatitis C, and HIV Policy Daniel Raymond Hepatitis C Policy Analyst Harm Reduction Coalition
Advocacy 1. What is Advocacy? ● Organized effort to influence policy change/decision making ● Action directed at changing approach of an individual/institution/group.
Organizing Drug Users for Community & Social Change.
Models of Harm Reduction
Promotores de Salud as New approach to the African American in the County of San Bernardino A partnership between two Community Based Organizations in.
HIV and Hepatitis C in non- MSM Rural Communities: Issues and Interventions Shari Wells-Weiss, CASAC Director of Prevention Services Southern Tier AIDS.
1 How ready are you to change prevention? Preparing an agency for Prevention with Positives.
Slide 5.1 Topic 5. Supporting programs aimed at reducing the spread of HIV among and from IDU Needle and Syringe Programs Opioid Substitution Treatment.
Edo Agustian Indonesian Drug Users Network Experiencing HCV Infection – the treatment, the reality and the possibilities for Cure.
Hepatitis and Liver Cancer A National Strategy for Prevention and Control of Hepatitis B and C.
Incorporating HIV and Viral Hepatitis Testing and Referral into Idaho Drug Court Programs Presented by Idaho Advisory Council on HIV and AIDS, Bebe Thompson,
New York Harm Reduction Educators (NYHRE) UPRISE Peer Training Program Uniting Peers for the Rights of Injectors and Sex Workers Everywhere 9 th National.
African Americans and HIV: CA Office of AIDS Response Michelle Roland, MD Chief, Office of AIDS California Department of Public Health.
HIV/AIDS in Prison Settings Dr. Monica Beg HIV/AIDS Unit, United Nations Office on Drugs and Crime, Krakow, Poland September 27, 2004.
Advancing HIV Prevention Programs on HBCU Campuses: Leveraging Programs, Policies and Partnerships.
Divergent Patterns of Amphetamine Use in the City and Rural Areas in Northwest Poland Sobeyko J (1), Leszczyszyn-Pynka M (2), Parczewski M (2), Burris.
NACO and NACP. Response of Govt to HIV National AIDS Control Programme (NACP) under Ministry of Health & Family Welfare in 1992 NACP I (1992 – 1999) NACP.
Breaking Down Barriers: Access to HIV Testing and Treatment for San Franciscans Affected by Mental Health and Substance Use Prepared for: HIV Prevention.
Larry Cuellar Adult Viral Hepatitis Prevention Coordinator Texas Department of State Health Services 2010 STREET OUTREACH WORKERS CONFERENCE June 21, 2010.
Harm Reduction.
Overview of Harm Reduction and Sterile Syringe Access Anna Benyo Syringe Access Policy Coordinator Harm Reduction Coalition New Jersey Syringe Access Informational.
HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania Signe ROTBERGA UNODC, Baltic States 5 November.
RCGP training online: new training in short bites Danny Morris, Expert Lead RCGP Hepatitis B and C Part 1.
Injecting Drug Use and Drug Led HIV in Nepal Bijay Pandey Recovering Nepal.
Hepatitis C, Drug Use and Stigma Liz Allen. What it is Hepatitis C? Hepatitis C is a blood-borne virus Can cause serious damage to the liver First indentified.
Innovative approaches to partnership between MSM/TG CBOs and clinical services – The Humsafar Model.
HIV Quality Learning Network Model AIDS Institute, NYSDOH Food and Nutrition Quality Learning Network Quality Learning Network Johanna Buck, Quality Consultant.
Funded by SAMHSA through the Garrett Lee Smith Campus Suicide Prevention Grant Program Cohort 1 and Cohort 3 ASU Campus Care
Learning journey Part 1: Welcome and introduction Part 2: Concepts, evidence, and good practice: Addressing gender-based violence and engaging men and.
November 2012 Prepared for the Contra Costa Board of Supervisors by Contra Costa Health Department Needle Exchange Update.
Medical Professionalism and its Relationship to Public Health: Physician Advocacy and State Public Health Policy Thomas Kellogg Program Officer and Advisor.
Office of Overseas Programming & Training Support (OPATS) HIV Prevention for Key Populations HIV Prevention.
Resource Needs Model Rachel Sanders October 28 th, 2010.
Lifting the Federal Ban on the funding of syringe exchange: An advocacy campaign Allan Clear XVIII International AIDS Conference.
Targeted Interventions for IDUs – an overview. Targeted Intervention for IDUs - an Overview 2 Background  In Asia, 4.7 million people were infected with.
STATE OF THE STATE SHELLEY LUCAS HIV/STD PREVENTION & CARE BRANCH DEPT OF STATE HEALTH SERVICES AUGUST 3, 2015.
Pennsylvania: The State of HCV 2015
Latino HIV Prevention Efforts California Department of Public Health Office of AIDS Catherine Lopez, M.Ed. OA Latino HIV Program and Policy Coordinator.
[IN-Mouraria/GAT LOGO] Harm reduction and HIV/HCV responses for several populations: the challenge of integrating responses Ricardo Fuertes, Adriana Curado,
Towards a Comprehensive Education Sector Response to HIV and AIDS UNESCO EFA Working Group 20 July 2006.
Prevention of Blood-Borne Pathogen Transmission in Egypt Ministry of Health and Population Arab Republic of Egypt.
Hepatitis C Support Groups Therapeutic BenefitsAdvocacy Benefits Patient education on disease state and treatment options Peer support Promote lifestyle.
Harm Reduction Team Maureen Woods Team Leader. Service Delivery Aims Develop harm reduction initiatives in partnership with other agencies to reduce the.
California Department of Public Health Office of AIDS HIV CARE and PREVENTION 2009: You Need to Know.
Social Work Competences by Kasey Ingram IDENTIFY AS A PROFESSIONAL SOCIAL WORKER Gained more knowledge about HIV/AIDS and HCV Advocated for clients.
1 NTA More treatment, better treatment, fairer treatment National injecting conference Annette Dale-Perera Director of Quality.
Hepatitis C Action Plan Local Authorities…… Local Authorities…… ….and how to engage them ….and how to engage them.
Marija Tosheva Advocacy Officer Sex Workers Rights Advocacy Network in CEECA (SWAN)
NDPHS Expert Group on HIV/AIDS and Associated Infections Draft problem tree 5 December, 2011 Chair Dr. Ali Arsalo and ITA Ms Outi Karvonen.
Organizing Drug Users for Public Health Policy Changes 17 th International Conference on the Reduction of Drug Related Harm Jason Farrell, Executive Director.
Edo Agustian Indonesian Drug Users Network Meaningful Involvement of PWID in Hep C advocacy in Indonesia.
Non-Medical Staff Knowledge, Beliefs and Practices about HIV and Hepatitis for Injection Drug Users Rowe, KA 1, Tesoriero, JM 1, Heavner, KK 1, Rothman,
HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania Riga, 29 May 2008 Sintija Šmite, UNODC.
Key Population Community taking the Lead.
Multnomah County Health Department
Tacoma Needle Exchange Tier Based Care Coordination
Preliminary Draft 5 Year Action Plan HIV, Hepatitis C, and STIs
ENDING THE EPIDEMICS: A FOCUS ON PEOPLE WHO INJECT DRUGS
State Response to Opioids and Infectious Disease
Blood borne viral hepatitis action in Wales
Human Dignity and Harm Reduction
Presentation transcript:

Working with SEPs: How do we expand Hepatitis Services ? Narelle Ellendon, RN HCV Director Harm Reduction Coalition, NYC

Why work with SEPs?  Prevent the spread of any blood-borne infections, including HIV and Hep C  Make and maintain contact with active injectors outside of the health care system  Varied delivery, size, nature, populations, etc, etc, etc…

Why SEPs ???  It’s not just the Syringes, it’s not just the SEP.  Bridge to treatment and other services - HIV testing & counseling - Medical & Mental health services - Case Management - Housing - Food programs - Support groups

SEP Participants  Many IDUs not using SEPs  More then half acquire syringes from potential unsterile source  Nearly half report “sharing” syringes and other equipment  Generally participants of SEPs have been injecting for some time  Large number of IDUs already infected with HCV

HCV Prevention Attitudes  HCV infection is INEVITABLE  HCV infection is INCONSEQUENTIAL  HCV infection is INDETERMINATE

Limitations of SEPs to address HCV?  Lack of expertise & training  Competing Priorities  Lack of referral options for DU’s  Funding Limitations  Regulations on syringe provision  Police Harassment  Federal ban

Where to begin……  Assessment: - Participant - Staff - Program Evaluation not just for Data. Process of assessment needs to provide Education & Interventions.

Adding Hep C…. One size does NOT fit all…  Tailoring Program Strategic Plan to the SEP.  HCV Networking, (Motivation & Position)  Tailored Training, (SEP Staff, Other services)  Peer Education  Manuals & Curriculum  Materials

Awareness…

Adding Hep C….  Build on existing assessment tools  HCV Screening & Hep A/B Vaccs services  Linkages to care & treatment

Advocacy  Local & National forums to bring the focus on Hepatitis C & Drug  Coaching/Mentoring internal program advocacy  Community focus, African Americans & HCV  Pharmaceutical companies  Funding

IDUs more likely to not be infected with HIV or HCV if…..  Avoid situations that threaten safe injection: - withdrawal period - lack of syringes - high-risk contexts - institutionalization  Match equipment supply with drug supply  Maintain connection with community

Opportunities….  Validate & Share IDUs strategies to avoid HCV Infection.  Change syringe quotas  Tap into Social Networks, Peer Secondary Exchange  Police/Community Education  Address stigma of Drug Users using other services  Federal Ban on $ for SEP  Safer Injecting Facilities